0.05Open0.20Pre Close1 Volume682 Open Interest5.00Strike Price5.00Turnover193.45%IV18.41%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1615Delta0.3911Gamma85.30Leverage Ratio-0.0348Theta0.0000Rho13.78Eff Leverage0.0008Vega
Olema Pharmaceuticals Stock Discussion
Cancer Breakthrough: New Drug OP-3136 Achieves 28-Day Tumor Regression in Multiple Cancer Types
Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025
Friday, 25th April at 1:00 pm
• Activity in preclinical models of ovarian, prostate, and non-small cell lung cancer supports potential utility of OP-3136, a KAT6 inhibitor, in indications beyond breast cancer
• Patient recruitment ongoing in Phase 1 trial of OP-3136 as a monotherapy and in combination regimens in multiple s...
Cancer Breakthrough: New Drug Shows Powerful Anti-Tumor Effects in Prostate, Ovarian, Lung Cancers
From past trends, December tends to be when the stock price takes a dive as investors are looking at other more dynamic stocks to invest in. Feb and Jul seems to be when the stock price tends to get an uplift. The drop off is especially drastic this Dec given the significant interest in all things crypto, Trump and AI related after the recent election.
There's been generally good news from Olem...
Olema set for an operatic debut at last | ApexOnco - Clinical Trials news and analysis
Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium
Olema Oncology announced updated clinical results for palazestrant combined with ribociclib in treating ER+/HER2- advanced or metastatic breast cancer. With a 12-month median follow-up, the study showed promising results with median progression-free survival (PFS) not yet reached. The 6-month PFS rate was 73% overall, wit...
Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination With Ribociclib at the San Antonio Breast Cancer Symposium
Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor
Olema Pharmaceuticals (Nasdaq: OLMA) announced FDA clearance of its Investigational New Drug (IND) application for OP-3136, a novel small molecule that inhibits KAT6, an epigenetic target involved in breast and other cancers. The company plans to initiate a Phase 1 clinical trial in early 2025. OP-3136 has shown promising preclinical activity ...
4 MINUTES AGO, 7:00 AM EST
VIA GLOBENEWSWIRE
Olema Oncology Announces New Clinical Trial Collaboration and Supply Agreement With Novartis in Frontline Metastatic Breast Cancer as Well as $250 Million Equity Private Placement
No comment yet